Furthermore, when used in combination with tamoxifen (TMX), at low concentrations equol competitively binds to ERα inhibiting TMX’s anti-tumor effects; whereas at high concentrations a synergistic anti-tumor effect is observed [122]. This evidence concerns the gene ESR1 and neoplasm.